Once-Weekly Cagrilintide for Weight Management in People with Overweight and Obesity: A Multicentre, Randomised, Double-Blind, Placebo-Controlled and Active-Controlled, Dose-Finding Phase 2 Trial
The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved
At the cellular level, GLP-1 binding to GLP-1R activates the Gs protein, stimulating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP) concentrations
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
A recently FDA-approved higher dose of Wegovy (Wegovy HD) is 7.2 mg, and may result in even more weight loss compared to the 2.4 mg dose
Unlike daily medications, the weekly GLP-1 dosing timeline offers flexibility in scheduling